Immuno-Oncology | Specialty

Bispecific Immunotherapy Elicits Intriguing Responses in Melanoma

April 19th 2015

IMCgp100 yielded long-lasting responses in patients with advanced melanoma, according to results from a 17-patient expansion cohort presented at the 2015 AACR Annual Meeting.

Nivolumab Improves Survival in Phase III Nonsquamous NSCLC Study

April 17th 2015

Nivolumab (Opdivo) improved survival versus docetaxel in patients with pretreated nonsquamous non–small cell lung cancer in the phase III CheckMate-057 trial.

Novel Doublet and Triplet Combo Studies Explode in Melanoma

April 16th 2015

In an interview with OncLive, Jeffrey S. Weber, MD, PhD, discussed combinations currently in development for patients with advanced metastatic melanoma, and key considerations in employing the new therapies in clinical practice.

Dr. Markman on the Future of Treatment for Ovarian Cancer

April 13th 2015

Maurie Markman, MD, national director, Cancer Treatment Centers of America, discusses what he sees as future treatment paradigms in ovarian cancer.

Immunotherapy Innovator Jedd Wolchok Honored

April 11th 2015

Jedd D. Wolchok, MD, PhD, played an important role in the development of ipilimumab, the first drug to target an immune checkpoint as an anticancer strategy. He was honored in the Melanoma category with a 2014 Giants of Cancer Care® award.

Dr. Sadelain on CAR T-Cell Therapies

April 10th 2015

Michel Sadelain, MD, PhD, Director, Center for Cell Engineering and Gene Transfer and Gene Expression Laboratory, Stephen and Barbara Friedman Chair, Memorial Sloan Kettering Cancer Center (MSK), discusses chimeric antigen receptor (CAR) t-cell therapies.

Agarwala Discusses Role of Cytokines in Changing Immunotherapy Landscape

April 10th 2015

To further understand how cytokines are used in today's landscape and what their role will be in the future, OncLive interviewed Sanjiv S. Agarwala, MD, Section Chief of Hematology/Oncology, St. Luke's Cancer Center, and professor of Medicine, Temple University.

Experts Explore Immunotherapy Frontier in Melanoma

April 10th 2015

Immunotherapy advances are among the emerging treatment approaches that make it an exciting time for patients with melanoma and their physicians.

Dr. Agarwala on the Role of Cytokines in the Immunotherapy Landscape

April 2nd 2015

Sanjiv S. Agarwala, MD, Chief of Medical Oncology, Hematology, St. Luke's Cancer Center and Temple University, discusses the differences between cytokines and other types of immunotherapies.

Dr. Garcia on Challenges With Immunotherapy in Prostate Cancer

April 1st 2015

Jorge A. Garcia, MD, Department of Hematology and Oncology, Cleveland Clinic, discusses some of the challenges with immunotherapy in prostate cancer.

Dr. Joseph on Necessary Improvements on Immunotherapy in Melanoma

March 31st 2015

Richard W. Joseph, MD, Department of Hematology/Oncology, Mayo Clinic, discusses some improvements needed in the field of immunotherapy as a treatment for melanoma.

Autologous Vaccine Delays Progression Following Surgery for Ovarian Cancer

March 30th 2015

Treatment with the immunotherapy Vigil delayed time to progression in all patients with stage III/IV ovarian cancer who were treated with the autologous tumor cell vaccine compared with those who were not in an open-label phase II trial.

Dr. Jedd Wolchok on Immunotherapy Toxicities

March 30th 2015

Jedd Wolchok, MD, PhD, chief, of Melanoma and Immunotherapeutics Service, Memorial Sloan Kettering Cancer Center, discusses the toxicities associated with immunotherapy.

Novel Therapies Needed for Muscle-Invasive Bladder Cancer

March 27th 2015

Anti-PD-L1 Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Potential Targets in Muscle-Invasive Bladder Cancer

March 27th 2015

Treating Relapsed Muscle-Invasive Bladder Cancer

March 27th 2015

Cisplatin-Based Therapy in Muscle-Invasive Bladder Cancer

March 27th 2015

Multidisciplinary Approach in Muscle-Invasive Bladder Cancer

March 27th 2015

Neoadjuvant and Adjuvant Therapy in Bladder Cancer

March 27th 2015